EUROAPI and Priothera enter into CDMO collaboration to advance oncology project

Core Insights - EUROAPI has signed a 5-year CDMO agreement with Priothera to develop and industrialize the manufacturing process of innovative complex molecules for blood cancers [1][12] - The collaboration focuses on mocravimod, an S1P1 receptor modulator aimed at treating hematological malignancies and enhancing CAR-T cell therapies [3][6] - The global oncology market is projected to grow significantly, with spending on cancer medicines expected to reach $375 billion by 2027, up from $196 billion in 2022 [6] Company Overview - EUROAPI is a leading player in active pharmaceutical ingredients, offering approximately 200 products and a wide range of technologies through its CDMO activities [14] - The company operates six manufacturing sites in Europe and serves customers in over 80 countries [7] - Priothera, founded in 2020, specializes in developing orally applied S1P receptor modulators and is backed by various international investors [8][3] Clinical Development - Mocravimod is currently in a global phase 3 trial enrolling around 250 adult Acute Myeloid Leukemia patients across the US, Europe, Asia, and Latin America [6] - The drug has received Orphan Drug designation from both the EMA and US FDA, indicating its potential significance in treating rare diseases [6] Market Context - The oncology segment is a major focus for EUROAPI's CDMO business, reflecting the increasing demand for innovative therapies in the cancer treatment landscape [1][12] - The collaboration with Priothera is expected to accelerate the late development of mocravimod, aiming for worldwide drug registration and commercialization by 2027 [13]